EVALUATION OF THE CONTENT OF C-REACTIVE PROTEIN AND TUMOR NECROSIS FACTOR-ALPHA IN ORAL FLUID AND SERUM OF PATIENTS WITH GENERALIZED PERIODONTITIS IN THE POST-COVID PERIOD
DOI:
https://doi.org/10.35220/2078-8916-2022-43-1.3Keywords:
generalized periodontitis, COVID-19, C-reactive protein, tumor necrosis factor alpha (TNF-α)Abstract
Purpose of the study – to evaluate the content and dynamics of C-reactive protein and TNF-α data in serum and oral fluid of the periodontal patients, depending on the methods of dental treatment in the postcovid period. Research methods. The object of the study were 160 patients with generalized periodontitis of I and II degree of development, chronic course, who in past was diagnosed with mild, moderate and severe course of coronavirus disease and 20 people with intact periodontium (healthy). The recruitment of patients and retrospective analysis of case histories was carried out on the basis of Ivano-Frankivsk OKL, City Clinical Hospital №1 IFMR on the basis of the approved application by the General Directors, in close cooperation with fellow pulmonologists and family doctors. The determination of C-RB and TNF-α was performed in two variants: in oral fluid and serum after discharge from the hospital, in the period before dental treatment, on the 30th and 180’th day. Scientific novelty. For the first time, data on the content of C-reactive protein and TNF-α in the serum and oral fluid of periodontal patients after discharge from the hospital due to coronavirus disease were studied and reveales evaluated ranges of both inflammatory markers in the period before dental treatment. The application of the proposed complex of drug treatment with the usage of the course of photodynamic therapy with laser “Helbo Thera Lite” in comparison with traditional approaches to treatment has been tested and obtained. Conclusions. The results of immunological screening of interleukin TNF-α and C-reactive protein in biological liquids and clinical observations of patients in the postcovid period indicates about close etiopathogenetic relationship between these diseases. The data obtained from the studied inflammatory markers can probably serve as a trigger for the exacerbation of many somatic chronic diseases during the postcovid syndrome in such patients and require further monitoring by clinicians.
References
World Health Organization. Novel Coronavirus ( 2019-nCoV) : Situation report. 2020. № 22. URL: https://apps.who.int/iris/handle/10665/330991.
Aspiration of periodontopathic bacteria due to poor oral hygiene potentially contributes to the aggravation of COVID-19 / Y. Takahashi et al. J Oral Sci. 2020. № 63. P. 1–3.
Periodontal pockets: A potential reservoir for SARS-CoV-2? / Z. Badran et al. Med Hypotheses. 2020. № 143. P. 109907.
SARS-CoV-2 detection in gingival crevicular fluid / S. Gupta et al. J Dent Res. 2020. 0022034520970536.
Periodontal tissues are targets for SARS-CoV-2: A post-mortem study / B. Matuck Fernandes et al. J Oral Microbiol. 2021. № 13. 1848135.
Is periodontal disease a risk factor for severe COVID-19 illness? / V. Pitones-Rubio et al. Med Hypotheses. 2020. № 144. 109969.
The impact of periodontal disease on hospital admission and mortality during COVID-19 pandemic / H. Larvin et al. Front Med (Lausanne). 2020. № 7. 604980.
Cron R., Behrens E.M. Cytokine Storm Syndrome. 1 ed. Cham : Springer Nature Switzerland AG ; Springer International Publishing, 2019.
Into the eye of the cytokine storm / J.R. Tisoncik et al. Microbiol Mol Biol Rev. 2012. № 76. P. 16–32.
Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China / D. Wang et al. JAMA. 2020. № 323. 1061–9.
Clinical characteristics of coronavirus disease 2019 in China / W.J. Guan et al. N Engl J Med. 2020. № 382. 1708–20.
Clinical and immunological features of severe and moderate coronavirus disease 2019 / G. Chen et al. J Clin Invest. 2020. № 130. 2620–9.
Multiple organ infection and the pathogenesis of SARS / J. Gu et al. J Exp Med. 2005. № 202. P. 415–24.
Laenger, FPulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19 / M. Ackermann et al. N. Eng. J. Med. 2020. № 383. P. 120–128.
Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study / N. Chen et al. Lancet. 2020. № 395. P. 507–513.
Good oral health reduces risk of fatal outcomes from COVID-19. URL: https://www.mcgill.ca/newsroom/channels/news/good-oral-health-reduces-risk-fataloutcomes-covid-19-330275.
Oral microbiome and SARS-CoV-2: Beware of lung co-infection / L. Bao et al. Frontiers in Microbiology. 2020. № 11. 1840. DOI: 10.3389/fmicb.2020.01840.
Botros N., Iyer P., Ojcius D.M. Is there an association between oral health and severity of COVID-19 complications? Biomedical Journal. 2020. № 43 (4). P. 325– 327. DOI: 10.1016/j.bj.2020.05.016.
Oral microbiome and SARS-CoV-2: Beware of lung co-infection / L. Bao et al. Frontiers in Microbiology. 2020. № 11. P. 1840. DOI: 10.3389/fmicb.2020.01840.
Cron R., Behrens E.M. Cytokine Storm Syndrome. 1 ed. Cham : Springer Nature Switzerland AG ; Springer International Publishing, 2019.
Мудра В. М. Вивчення рівня прозапальних цитокінів (ФНПα, iL-1β) у сироватці крові та їхньої продукції в культурах мононуклеарів хворих на хронічний генералізований пародонтит, які потребують дентальної імплантації. Імплантологія. Пародонтологія. Остеологія. 2008. № 2. С. 11–13.
Посібник з лабораторної імунології / Л.Є. Лаповець та ін. Львів, 2008. 266 с.
Цитокіни: діагностичні можливості і перспективи використання в хірургічній стоматології / В.П. Цюрик та ін. Галицький лікарський вісник. 2002. Т. 9. № 1. С. 144–150.
Slade G.D. Acute-phase inflammatory response to periodontal disease in the US population. Journal of Dental Research. 2000. Vol. 79. Issue 1. Р. 49–57.
Gabay C. Acute phase proteins and other systemic responses to inflammation. New England Journal of Medicine. 1999. Vol. 340. Issue 6. Р. 448–454.
Prognostic value of C-reactive protein in patients with COVID-19 / X. Luo et al. Clin Infect Dis. 2020. № 71. P. 2174–2179.
Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments / G. Kokkotis et al. Aliment Pharmacol Ther. 2022. Jan. № 55 (2). P. 154–167.
The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19 / P.C. Robinson et al. Med (N Y). 2020. № 1 (1). P. 90–102.
Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry / E.J. Brenner et al. Gastroenterology. 2020. № 159 (2). P. 481–491.
Oral manifestations in patients with COVID-19: a living systematic review / J. Amorim dos Santos et al. Journal of Dental Research. 2021. № 100. P. 141–154.
Anaya‐Saavedra G. Oral manifestations accompanying and related to COVID‐19: Overlooking the obvious. Oral Diseases. 2021.
Increased Serum Levels of Soluble TNF-α Receptor Is Associated With ICU Mortality in COVID-19 Patients / E. Mortaz et al. Front Immunol. 2021. Apr. 22. № 12. 592727.
